Form 4: Suvretta Capital and Affiliates Increase Stake in Benitec Biopharma

Suvretta Capital Management and related entities have reported purchasing additional shares of Benitec Biopharma, increasing their holdings.

Summary

• Suvretta Capital Management, along with Averill Master Fund, Averill Madison Master Fund, and Aaron Cowen, have filed a Form 4 indicating changes in their beneficial ownership of Benitec Biopharma Inc. stock.
• On December 3, 2024, Averill Master Fund purchased 37,190 shares of common stock at $9.60 per share.
• On the same day, Averill Madison Master Fund purchased 4,810 shares of common stock, also at $9.60 per share.
• Following these transactions, Averill Master Fund now beneficially owns 7,957,365 shares, and Averill Madison Master Fund owns 955,124 shares.
• Suvretta Capital is the investment manager for both Averill Master Fund and Averill Madison Master Fund, and Aaron Cowen may be deemed to control Suvretta Capital.

Sentiment

Score: 6

Explanation: The document indicates increased investment by a major shareholder, which is generally a positive sign, but it is a routine filing and does not provide any information about the company's performance or future outlook.

Positives

• The increased investment by Suvretta Capital and its affiliates suggests confidence in Benitec Biopharma's future prospects.
• The purchases were made at a price of $9.60 per share, indicating a willingness to invest at the current market price.

Risks

• The document does not provide any specific risks, but it is important to note that all investments carry inherent risks.
• The Form 4 filing only reflects changes in ownership and does not provide any information about the company's performance or future outlook.

Industry Context

This filing reflects the ongoing investment activity in the biotechnology sector, where institutional investors often take significant positions in companies with promising technologies.

Comparison to Industry Standards

• Form 4 filings are a standard regulatory requirement for reporting changes in beneficial ownership by insiders and large shareholders in publicly traded companies.
• The reported transactions are typical for investment funds and managers who actively manage their portfolios.
• The size of the transactions is not unusual for a company of Benitec Biopharma's market capitalization.

Stakeholder Impact

• The increased investment may be viewed positively by shareholders, potentially increasing confidence in the company.
• The transactions do not have any immediate impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Benitec Biopharma, Suvretta Capital Management, Averill Master Fund, Averill Madison Master Fund, Aaron Cowen, share purchase, beneficial ownership, Form 4, investment